PharmaShots | Incisive News in 3 Shots

Subscribe Now

Agitation

Neumora Therapeutics Commences the P-Ib Trial of NMRA-511 to Treat Agitation Due to Alzheimer’s Disease

Neumora Therapeutics Commences the P-Ib Trial of NMRA-511 to Treat Agitation Due to Alzheimer’s Disease

June 21, 2024

Otsuka Reports Results from the P-III Study of AVP-786 for Treating Agitation in Patients with Dementia Due to Alzheimer's Disease

Otsuka Reports Results from the P-III Study of AVP-786 for Treating Agitation in Patients with Dementia Due to Alzheimer's Disease

February 14, 2024

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer’s Disease

Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due...

May 12, 2023

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Sch...

April 7, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us